TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 0 8 OCT 2004

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

10/511026 PRIORITY DATE CLAIMED

TIONAL APPLICATION NO. PCT/DE03/01203

INTERNATIONAL FILING DATE April 10, 2003

April 10, 2002

TITLE OF INVENTION

	USE OF PYRIMIDINE NUCLEOTIDES FOR THE TREATMENT OF AFFECTIONS OF THE PERIPHERAL NERVOUS SYSTEM
APPLI	CANT(S) FOR DO/EO/US  Hedding-Eckerich
Applica	ant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1. 🔽	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. 🔽	The US has been elected (Article 31).
5. 🔽	A copy of the International Application as filed (35 U.S.C. 371(c)(2))
	a. is attached hereto (required only if not communicated by the International Bureau).
	b. has been communicated by the International Bureau.
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
	a. is attached hereto.
	b. has been previously submitted under 35 U.S.C. 154(d)(4).
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
	a. are attached hereto (required only if not communicated by the International Bureau).
	b. have been communicated by the International Bureau.
	c. have not been made; however, the time limit for making such amendments has NOT expired.
	d. have not been made and will not be made.
8. 🔽	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. 🔲	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
Iten	ns 11 to 20 below concern document(s) or information included:
11. 🔽	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. 🔽	A preliminary amendment.
14.	An Application Data Sheet under 37 CFR 1.76.
15. 🔲	A substitute specification.
16.	A power of attorney and/or change of address letter.
17. 🔲	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18.	A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. 🔲	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. 🔽	Other items or information:
	Express Mail Certificate Blank Declaration and Power of Attorney

DT05 Rec'd PCT/PTO 0 8 OCT 2004

**Docket No.:** 

**ARTHP110US** 

**Applicant:** 

**Hedding-Eckerich** 

Title:

**USE OF PYRIMIDINE NUCLEOTIDES FOR THE** 

TREATMENT OF AFFECTIONS OF THE PERIPHERAL

**NERVOUS SYSTEM** 

I hereby certify that the attached patent application (along with any other paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on this date <u>October 8, 2004</u>, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV373134267US</u> addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Rebecca A. Bellas

(Typed or Printed Name of Person Mailing Paper)

(Signature of Person Mailing Paper)